4.7 Article

Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Virology

Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies

Marie Tre-Hardy et al.

Summary: The study assessed the performance of two ELISA tests for detecting antibodies against SARS-CoV-2 nucleocapsid protein, showing satisfactory analytical performance and excellent clinical performance for IgG, IgA, and total antibodies, especially with optimized cut-offs.

JOURNAL OF MEDICAL VIROLOGY (2021)

Article Infectious Diseases

Comparison of four commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT findings

Jens T. Van Praet et al.

Summary: Some Covid-19 patients may have negative RT-PCR results but suspicious CT findings. A study using four commercially available anti-SARS-CoV-2 IgG immuno-assays found that this subset accounted for 9.2% of consecutively admitted outpatients with Covid-19 in the hospital. However, the clinical specificity of some N protein-based immuno-assays for Covid-19 was suboptimal, as positive results were observed in patients with other recent viral infections.

INFECTION (2021)

Article Infectious Diseases

A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization

David Peterhoff et al.

Summary: The study developed a specific and sensitive enzyme linked immunosorbent assay (ELISA) for detection of anti-SARS-CoV-2 antibody levels. The ELISA showed high specificity and strong correlation in detecting SARS-CoV-2 antibodies, and was able to generate robust antibody levels 10 days after symptom onset.

INFECTION (2021)

Article Cell & Tissue Engineering

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Shi Xiaojie et al.

Summary: Since it was first identified in Wuhan, China at the end of 2019, SARS-CoV-2 causing the worldwide pandemic has dramatically changed people's lives in multiple aspects. Efforts to curb the progression of the pandemic are urgently ongoing, with promising therapeutic antibodies being developed through various approaches. Studies have shown that neutralizing antibodies against SARS-CoV-2 are mainly targeting the RBD and some non-RBD domains, with convergent germline genes identified for effective antibodies.

STEM CELL RESEARCH (2021)

Article Medicine, General & Internal

The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro

Niko Kohmer et al.

Summary: The sensitivity of SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) for rRT-PCR positive samples is relatively low, but they show high positivity rates for samples with high viral load, especially in infectious individuals. Not all rRT-PCR positive samples are infectious, while Ag-RDTs demonstrate a better correlation with cell culture infectivity. These findings suggest that large-scale SARS-CoV-2 Ag-RDT-based testing can be effective in detecting potentially infective individuals and reducing virus spread.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Medicine, General & Internal

Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies

Anja Doerschug et al.

Summary: Serological assays can be used to estimate the population's exposure to the SARS-CoV-2 virus, with varying sensitivity and specificity observed in different diagnostic assays for SARS-CoV-2-specific antibodies. Immunoglobulin G showed the best results in terms of sensitivity and agreement between different assays.

DIAGNOSTICS (2021)

Article Infectious Diseases

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

Vivian Glueck et al.

Summary: This study followed the serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for 30 weeks, finding that the majority retained IgG antibodies after 12 weeks and 90% remained positive at 30 weeks, while IgA and IgM responses declined more rapidly, with a portion of participants no longer having detectable antibodies at 30 weeks.

INFECTION (2021)

Article Infectious Diseases

Comparison of six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use

Anna Christine Nilsson et al.

Summary: This study evaluated six commercial serological assays for detection of SARS-CoV-2 antibodies, finding that ELISA assays are most suitable for mild cases, while Livzon LFT and Euroimmun ELISA have the highest specificity, making them suitable for seroprevalence studies.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Article Biochemical Research Methods

Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2

Felipe Perez-Garcia et al.

Summary: The study compared the diagnostic performance of six immunoassays to detect antibodies against SARS-CoV-2, with One Step, Dia.Pro, Elecsys, and COV2T showing the best results, with sensitivities over 97% from 14 days after symptom onset.

JOURNAL OF VIROLOGICAL METHODS (2021)

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Article Medicine, General & Internal

Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests

Diego O. Andrey et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Article Virology

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Niko Kohmer et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Article Virology

Comparison of different serological assays for SARS-CoV-2 in real life

Etienne Brochot et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Review Medicine, General & Internal

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Gregory A. Poland et al.

LANCET (2020)

Editorial Material Infectious Diseases

The complexities of SARS-CoV-2 serology Comment

Catherine F. Houlihan et al.

LANCET INFECTIOUS DISEASES (2020)

Article Biotechnology & Applied Microbiology

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

Jeffrey D. Whitman et al.

NATURE BIOTECHNOLOGY (2020)

Review Microbiology

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Wen Shi Lee et al.

NATURE MICROBIOLOGY (2020)

Article Multidisciplinary Sciences

Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality

Viola Hahnel et al.

PLOS ONE (2020)